Lingual hyperpigmentation after 5-fluorouracil chemotherapy

Co, Michael; Esteban, Marcus Juan

doi:10.1136/bcr-2017-219806

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obtaining detailed data on all skin and oral pigmentations was thus difficult. Although few reports have described oral and skin pigmentation simultaneously, some reports have described oral pigmentation occurring without skin pigmentation (15,22,23). However, all 11 patients in this study showed skin pigmentation.…”

Section: Discussioncontrasting

confidence: 48%

“…Treatment for pigmentation includes waiting for spontaneous resolution. Pigmentation of the skin and oral mucosa is generally considered likely to improve within a few months after discontinuation of the causative agent (11,15,(22)(23)(24). However, a case with improvement, but not resolution, of pigmentation in the oral mucosa after 18 months of follow-up has been reported (25).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cancer Chemotherapy-associated Pigmentation of the Oral Mucosa

Yamada

Iijima

Seo

et al. 2023

In Vivo

View full text Add to dashboard Cite

Background/Aim: Oral adverse events caused by anticancer drugs are diverse, but few reports have examined pigmentation of the oral mucosa. The aim of this study was to clarify the prevalence of oral mucosal pigmentation caused by anticancer drugs. Patients and Methods: This single-centre retrospective study investigated patients who underwent oral examination in our hospital during cancer chemotherapy for 3 years from April 1, 2019 to March 31, 2021. Inclusion criteria were patients who could be followed-up for ≥3 months after completing chemotherapy with drugs that caused pigmentation. The primary predictive variable was the cancer chemotherapeutic agent used. The primary outcome variable was pigmentation of the oral mucosa. Collected data were statistically analysed using the χ 2 test or Fisher's exact test, with the level of significance set at p<0.05. Results: A total of 388 patients were enrolled in the study. Eleven patients (2.8%) showed oral mucosal pigmentation. Drugs causing pigmentation [deposition rate (number of patients with deposits/users)] were gimeracil, and oteracil potassium) [12.2% (5/41)], paclitaxel [4.0% (2/50)], gemcitabine [5.0% (1/20)], cyclophosphamide [2.3% (1/42)], carboplatin [1.6% (1/64)], fluorouracil [2.3% (1/43)], and capecitabine [3.4% (1/29)]. Conclusion: Oral pigmentation due to cancer chemotherapy was found in 2.8% of patients. TS-1, carboplatin, cyclophosphamide, capecitabine, fluorouracil, gemcitabine, and paclitaxel caused pigmentation of the oral mucosa. Among these, TS-1 was the most likely to cause pigmentation, affecting 12.2% of users.

show abstract

Section: Discussioncontrasting

confidence: 48%

Section: Discussionmentioning

confidence: 99%

Cancer Chemotherapy-associated Pigmentation of the Oral Mucosa

Yamada

Iijima

Seo

et al. 2023

In Vivo

View full text Add to dashboard Cite

show abstract

“…Oral hyperpigmentation induced by chemotherapeutic and antineoplastic agents was reported in 30 and 125 patients, respectively. The most prevalent agent was imatinib 18,21,22,24,36,46,[48][49][50][51][52][53][54][55]57,62 other agents included capecitabine, 16 cyclophosphamide, 25,40 5-fluorouracil, 43 irinotecan, 26 and hydroxyurea. 11 The risk of oral pigmentation in association with imatinib therapy increased as the duration of intake increased (an average of 7 years) and occurred most commonly in the hard palate.…”

Section: Dovepressmentioning

confidence: 99%

<p>Medication-Induced Oral Hyperpigmentation: A Systematic Review</p>

Binmadi¹,

Bawazir²,

Alhindi³

et al. 2020

PPA

View full text Add to dashboard Cite

Background: Medication-induced oral hyperpigmentation is an oral condition that impacts patients' quality of life and has been linked to many systemic therapeutic agents. The exact pathogenesis of tissue pigmentation varies greatly and is not completely known. This systematic review aimed to present data on the causal association between medications and the development of oral/mucosal pigmentation as an adverse drug reaction. Methods: A systematic review and analysis of literature were conducted using the following databases: PubMed, Science Direct, ProQuest, Web of Science, and Scopus. The systematic review included original articles written in English and published between January 1982 and June 2020. Following the PRISMA statement, eligible articles were systematically reviewed, and data were extracted from eligible studies and analyzed. Results: A total of 235 articles were identified, of which 57 met the inclusion criteria and were included in this review. The mean age of included patients was 46.2±16.38 years (range: 10-90 years) with a male to female ratio of 1:1.45. Oral mucosal hyperpigmentation was reported following the use of several classes of medications such as antiviral (eg, zidovudine), antibiotic (eg, minocycline), antimalarial (eg, chloroquine), anti-fungal (eg, ketoconazole), antileprotic (eg, clofazimine), antihypertensive (eg, amlodipine), chemotherapeutic, and antineoplastic drugs. The risk of developing oral pigmentation was significantly higher with antimalarial medications, antibiotics, antineoplastic and chemotherapeutic agents. Medication-induced oral hyperpigmentation was most frequent among women and in the hard palate. Conclusion: Future research is warranted to better understand the pathogenesis and risk factors for medication-induced oral hyperpigmentation in order to reassure patients during prescription and management.

show abstract

Bevacizumab/fluorouracil

2017

Reactions Weekly

View full text Add to dashboard Cite

Lingual hyperpigmentation after 5-fluorouracil chemotherapy

Cited by 3 publications

References 5 publications

Cancer Chemotherapy-associated Pigmentation of the Oral Mucosa

Cancer Chemotherapy-associated Pigmentation of the Oral Mucosa

<p>Medication-Induced Oral Hyperpigmentation: A Systematic Review</p>

Bevacizumab/fluorouracil

Contact Info

Product

Resources

About